医疗设备病毒灭活检测市场：按技术、检测类型、设定、样本类型、应用和最终用户划分－全球预测，2026-2032年

2025 年医疗设备病毒灭活检测市场价值为 2.0744 亿美元，预计到 2026 年将成长至 2.3032 亿美元，预计到 2032 年将达到 4.6068 亿美元，复合年增长率为 12.07%。

关键市场统计数据
基准年 2025	2.0744亿美元
预计年份：2026年	2.3032亿美元
预测年份 2032	4.6068亿美元
复合年增长率 (%)	12.07%

本文简要概述了病毒灭活检测对临床检查室、生产商和研究实验室不断变化的优先事项和战略意义。

病毒灭活检测领域正经历快速变化，这主要受到公共卫生优先事项、生物製造需求和诊断复杂性的共同影响。本执行摘要探讨了当前影响该领域的核心主题，包括技术多样化、诊断和生产流程的整合以及监管作用的日益增强。报告重点阐述了检测方法如何与临床、研究和工业环境中的应用需求和操作限制相匹配。

技术多元化和监管重点如何重塑病毒灭活检测生态系统中的采购、验证方法和营运协作

过去几年，受技术成熟、需求多元化和监管趋严的驱动，病毒灭活检测生态系统发生了变革性变化。首先，检验的方法组合已从传统的加热和化学方法扩展到先进的过滤系统和靶向紫外线照射平台，每种方法都旨在应对不同的风险、通量和基质相容性要求。这种多元化使得通讯协定能够根据具体应用进行客製化，从即时检测检体处理到大规模疫苗生产均可适用。

评估2025年关税调整如何改变了测试和生产相关人员的供应链韧性、筹资策略和营运决策。

2025年前后实施的累积关税调整对病毒灭活检测供应链产生了显着影响。进口零件、设备和某些化学试剂的关税调整增加了许多依赖全球采购的实验室和製造商的现场成本。这些成本波动迫使采购团队重新评估供应商集中度、前置作业时间缓衝以及资本设备和持续耗材的总拥有成本 (TCO)。

综合細項分析揭示了技术选择、应用需求、最终用户需求、检体方法和运行环境如何决定灭活策略的选择。

详细的細項分析揭示了技术、应用、最终用户、样品类型、检测方法和操作环境如何造成不同的需求和采用模式。化学灭活、过滤、热处理和紫外线C波段照射等技术各自具有不同的风险特征和基质相容性。化学方法具有柔软性，可适应各种样品类型；过滤提供适用于液体基质的物理去除方法；热处理是一种成熟的频谱方法，可在受控环境下进行；紫外线C波段照射提供了一种非化学灭活方法，对于需要最大限度减少残留物的流程来说极具吸引力。这些技术的选择取决于下游分析的灵敏度要求以及所处理生物材料的性质。

区域比较分析：采购重点、监管协调与生产概况如何影响病毒灭活检测解决方案的采用

区域趋势正在影响美洲、欧洲、中东和非洲以及亚太地区的采购、监管预期和应用路径。在美洲，临床检查室和製造商致力于在保持快速诊断和生产扩张弹性的同时，协调遵守各国法规结构。该地区也在推行区域筹资策略，以降低贸易相关的成本波动，并强调快速部署以及与现有实验室资讯系统的互通性。

现有企业、专业技术供应商和服务实验室透过验证协助、整合工作流程和本地服务能力来脱颖而出。

病毒灭活检测领域的竞争格局呈现出多元化的特点，既有成熟的生命科学仪器供应商，也有拥有单一检测平台的专业厂商，还有提供端到端验证服务的综合服务实验室。成熟的仪器製造商利用其广泛的分销网络和检验的工程及服务基础设施，服务于大规模医院系统和製造商；而专业厂商则专注于技术差异化，例如优化的UV-C照射系统或针对特定基质设计的新型过滤介质。

为检查室和生产领导者提供可操作的策略重点，以加强供应链韧性、验证工作流程和营运准备，从而实现持续的测试效能。

产业领导者应采取多管齐下的策略，全面应对营运韧性、验证严谨性和客户支援等问题。首先，应实现供应商关係多元化，考虑区域采购和本地组装，以降低关税波动带来的成本风险并缩短前置作业时间。其次，应投资模组化验证框架和数位化记录系统，以加快不同地点间的方法转移，并支援符合监管检查要求的统一文件。

本研究采用综合性的混合方法研究设计，结合相关人员访谈、技术文献综述和情境分析，旨在检验营运洞察与采购启示。

本研究采用混合方法，结合关键相关人员访谈、专家咨询和二手技术文献回顾，全面了解病毒灭活检测的现况。主要资讯来源包括与临床、研究和生产环境中的实验室主任、品质保证人员、采购专业人员和技术营运经理进行的结构化讨论。这些讨论重点关注操作限制、技术在实际环境中的性能以及检验要求。

策略需求综合分析强调检验、互通性和供应商韧性是病毒灭活测试中持续营运绩效的决定因素。

总之，病毒灭活检测已成为临床检查室、研究实验室和製造商业务决策的核心。为满足特定样本基质和通量需求，技术选择日趋多样化，而日益增长的监管和采购压力也使得可靠的验证、数位化记录和供应商韧性变得更加重要。在贸易政策不断变化和品质要求日益提高的环境下，那些积极主动地将技术选择与应用需求相匹配，并投资于跨职能检验能力的组织，将更有利于实现营运连续性和降低风险。

目录

第一章：序言

第二章调查方法

• 研究设计
• 研究框架
• 市场规模预测
• 数据三角测量
• 调查结果
• 调查前提
• 调查限制

第三章执行摘要

• 首席体验长观点
• 市场规模和成长趋势
• 2025年市占率分析
• FPNV定位矩阵，2025
• 新的商机
• 下一代经营模式
• 产业蓝图

第四章 市场概览

• 产业生态系与价值链分析
• 波特五力分析
• PESTEL 分析
• 市场展望
• 上市策略

第五章 市场洞察

• 消费者洞察与终端用户观点
• 消费者体验基准
• 机会地图
• 分销通路分析
• 价格趋势分析
• 监理合规和标准框架
• ESG与永续性分析
• 中断和风险情景
• 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章医疗设备病毒灭活检测市场（依技术划分）

• 化学
• 过滤
• 热处理
• 紫外线（UV-C）照射

第九章 依检测方法分類的医疗设备病毒灭活检测市场

• 定性
• 定量

第十章 按安装位置分類的医疗设备病毒灭活测试市场

• 实验室
• 护理点

第十一章 依检体类型分類的医疗设备病毒灭活检测市场

• 血液样本
• 环境样品
• 组织样本

第十二章医疗设备病毒灭活检测市场（依应用领域划分）

• 诊断测试
  • 医院检查室
  • 即时检测
• 研究用途
• 消毒服务
• 疫苗生产
  • 灭活疫苗
  • 减毒活病毒疫苗
  • 重组疫苗

第十三章医疗设备病毒灭活检测市场（依最终用户划分）

• 诊断中心
• 医院和诊所
• 製药公司
• 研究所

第十四章医疗设备病毒灭活检测市场（按地区划分）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十五章医疗设备病毒灭活检测市场（依组别划分）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十六章 各国医疗设备病毒灭活检测市场

• 我们
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

17. 美国医疗设备病毒灭活检测市场

第十八章：中国医疗设备病毒灭活检测市场

第十九章 竞争情势

• 市场集中度分析，2025年
  • 浓度比（CR）
  • 赫芬达尔-赫希曼指数 (HHI)
• 近期趋势及影响分析，2025 年
• 2025年产品系列分析
• 基准分析，2025 年
• Bertin Technologies
• BioMrieux
• Charles River Laboratories
• Ecovadis
• Lonza
• MedDevice
• Merck KGaA
• Pall Corporation
• SGS
• Sterigenics
• The Biovac Initiative
• Thermo Fisher Scientific
• ViroStat
• WuXi AppTec

The Medical Device Viral Inactivation Testing Market was valued at USD 207.44 million in 2025 and is projected to grow to USD 230.32 million in 2026, with a CAGR of 12.07%, reaching USD 460.68 million by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 207.44 million
Estimated Year [2026]	USD 230.32 million
Forecast Year [2032]	USD 460.68 million
CAGR (%)	12.07%

Concise orientation to the evolving priorities and strategic implications of viral inactivation testing for clinical laboratories, manufacturers, and research institutions

The landscape for viral inactivation testing is evolving rapidly as public health priorities, biomanufacturing demands, and diagnostic complexity converge. This executive summary introduces the core themes that shape the discipline today, including technological diversification, integration across diagnostic and production workflows, and the heightened role of regulatory oversight. It places particular emphasis on how testing modalities align with application needs and operational constraints in clinical, research, and industrial settings.

As organizations work to maintain biosafety and product integrity, viral inactivation testing has shifted from a compliance-driven checkbox to a strategic capability. Laboratories and manufacturers must align method selection with sample matrix characteristics, turnaround expectations, and downstream use cases. The introduction frames subsequent sections by laying out the transformational shifts in delivery models, the trade environment implications for 2025, and segmentation and regional perspectives that decision-makers need to prioritize when planning investments in equipment, consumables, and technical expertise.

How technological diversification and regulatory emphasis are reshaping procurement, validation practices, and operational collaboration across the viral inactivation testing ecosystem

Over the past several years, the viral inactivation testing ecosystem has experienced transformative shifts driven by technological maturation, demand-side diversification, and regulatory tightening. First, the portfolio of validated approaches has broadened beyond traditional heat and chemical methods to include advanced filtration systems and targeted UV-C irradiation platforms, each designed to meet different risk, throughput, and matrix compatibility profiles. This diversification is enabling practitioners to tailor protocols to specific applications, from point-of-care specimen handling to large-scale vaccine production.

Second, adoption patterns have changed as diagnostic testing moved closer to the patient and as vaccine manufacturing scaled to meet global needs. Point-of-care settings increasingly require rapid, reliable inactivation steps that preserve diagnostic targets, while production environments prioritize high-throughput methods that maintain antigenic integrity for downstream formulation. Concurrently, cross-functional collaboration between quality assurance, regulatory affairs, and laboratory operations has become more pronounced, because validation requirements now extend to process controls, traceability, and documentation spanning the whole lifecycle of a test or product.

Third, data-centric validation and digital recordkeeping are growing in importance. Laboratories and manufacturers are integrating automated logging, instrument connectivity, and auditable workflows to meet both internal quality goals and external regulatory scrutiny. Taken together, these shifts are reshaping procurement decisions, staffing profiles, and the competitive landscape for providers of instruments, consumables, and validation services.

Assessment of how 2025 tariff adjustments have altered supply chain resilience, procurement strategies, and operational decisions across testing and production stakeholders

The cumulative impact of tariff changes enacted in and around 2025 has introduced material implications for supply chains supporting viral inactivation testing. Tariff adjustments on imported components, instrumentation, and certain chemical reagents have increased landed costs for many laboratories and manufacturers that rely on global sourcing. These cost dynamics have forced procurement teams to reassess supplier concentration, lead-time buffers, and the total cost of ownership for capital equipment and recurring consumables.

In response, organizations have pursued several adaptive strategies. Some have diversified supplier portfolios to include regional vendors or alternative component sources to mitigate single-origin exposure. Others have moved toward greater inventory buffering and negotiated longer-term purchase agreements to stabilize pricing. In certain cases, manufacturers of testing platforms have localized assembly or component supply to soften tariff effects and preserve competitive pricing for strategic customers. These shifts have also altered the calculus for warranty and service contracts, as cross-border maintenance and parts replacement now carry additional logistical and cost considerations.

Furthermore, the tariff environment has sharpened the focus on operational efficiency. Process optimization and increased in-house validation capacities have become pragmatic responses to offset pricing pressures. Across the sector, stakeholders are balancing near-term procurement constraints with longer-term choices about supplier relationships, vertical integration, and resilient operational models that maintain continuity of testing and production under shifting trade conditions.

Integrated segmentation analysis revealing how technology choices, application demands, end-user needs, sample matrices, testing approaches, and operational settings determine inactivation strategy selection

A granular segmentation lens clarifies how technology, application, end-user, sample type, testing approach, and operational setting drive distinct needs and adoption patterns. Technologies such as chemical inactivation, filtration, heat treatments, and UV-C irradiation serve different risk profiles and matrix compatibilities: chemical approaches often offer flexibility for diverse sample types, filtration delivers physical removal suitable for fluid matrices, heat is a well-understood broad-spectrum method for controlled environments, and UV-C irradiation provides non-chemical inactivation attractive for workflows requiring minimal residuals. The choice among these technologies depends on downstream analytical sensitivity requirements and the nature of the biological material being processed.

Applications span diagnostic testing, research functions, sterilization services, and vaccine production, each with their own performance and documentation expectations. Diagnostic testing includes hospital laboratory workflows and point-of-care testing, which demand rapid, standardized inactivation that preserves diagnostic targets and supports quick turnaround. Vaccine production requires approaches that protect antigenic structures across inactivated vaccines, live attenuated formulations, and recombinant platforms, where inactivation must be validated extensively to ensure safety without compromising efficacy. Research applications and sterilization services add another dimension, emphasizing protocol flexibility, reproducibility, and compatibility with diverse experimental designs.

End users include diagnostic centers, hospitals and clinics, pharmaceutical companies, and research laboratories, and each setting enforces distinct operational priorities from regulatory compliance and patient safety to batch consistency and experimental rigor. Sample types range from blood and tissue samples to environmental swabs, influencing method selection because matrix effects can markedly alter inactivation kinetics and downstream assay performance. Testing approaches vary between qualitative and quantitative modalities, with qualitative methods focused on presence/absence determinations and quantitative methods providing titers or log-reduction metrics critical for production and validation. Finally, the operational setting-whether lab-based or point-of-care-affects instrument footprint, ease of use, and validation burden, leading organizations to choose solutions that balance accuracy, throughput, and operational practicality.

Regional comparative insights showing how procurement priorities, regulatory harmonization, and manufacturing profiles influence the adoption of viral inactivation testing solutions

Regional dynamics influence procurement, regulatory expectations, and the pathways to adoption across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, clinical laboratories and manufacturers are focused on harmonizing compliance with domestic regulatory frameworks while maintaining agility for rapid diagnostic and production scaling. This region often emphasizes rapid deployment and interoperability with existing laboratory information systems, while also pursuing localized sourcing strategies to mitigate trade-related cost volatility.

In Europe, Middle East & Africa, regulatory harmonization across multiple jurisdictions elevates the importance of standardized validation and high-quality documentation. Stakeholders in this region frequently prioritize solutions that demonstrate cross-border regulatory acceptance and accommodate a broad range of healthcare delivery contexts, from advanced tertiary centers to constrained resource environments. The emphasis on environmental sustainability and energy efficiency also influences technology selection in sterilization and inactivation choices.

Asia-Pacific features both high-volume manufacturing hubs and fast-growing point-of-care networks, which leads to divergent needs within the region. Manufacturers prioritize high-throughput, scalable inactivation methods that integrate with production lines, while emerging healthcare markets emphasize compact, easy-to-use solutions suited to decentralized testing. Across all regions, regional supplier ecosystems, tariff considerations, and local regulatory pathways shape procurement strategies and the rate at which new technologies move from validation to routine use.

How incumbents, niche technology providers, and service laboratories are differentiating through validation support, integrated workflows, and localized service capabilities

Competitive dynamics within the viral inactivation testing space are characterized by a blend of established life-science instrument providers, niche specialists in single-method platforms, and integrated service laboratories offering end-to-end validation. Established instrument manufacturers leverage broad distribution networks, validated engineering, and service infrastructures to serve large hospital systems and manufacturers, while specialized vendors focus on technology differentiation such as optimized UV-C delivery systems or novel filtration media designed for specific matrices.

Service laboratories and validation consultancies play an increasingly strategic role by combining technical protocol development, third-party verification, and operational support that reduces time to compliance. These players often partner with instrument vendors or reagent suppliers to deliver bundled solutions that include method transfer, training, and documentation packages that meet regulatory expectations. Strategic partnerships and co-development arrangements are also common, as platform vendors seek to embed consumable pipelines and locked-in consumable ecosystems that enhance customer retention.

Across the competitive field, differentiation is achieved through demonstrable validation data, user-friendly workflow integration, robust service networks, and documented compliance with relevant standards. Vendors that can offer scalable solutions across laboratory and production settings, along with flexible commercial terms and localized support, are best positioned to capture attention from both clinical and industrial buyers. Ultimately, the ability to link technical performance with operational savings and regulatory readiness is the most persuasive value proposition in this space.

Actionable strategic priorities for laboratory and manufacturing leaders to enhance supply chain resilience, validation workflows, and operational readiness for sustained testing performance

Industry leaders should pursue a multi-pronged strategy that addresses operational resilience, validation rigor, and customer enablement. First, diversify supplier relationships and explore regionalized sourcing or localized assembly to reduce exposure to tariff-driven cost fluctuations and to shorten lead times. Second, invest in modular validation frameworks and digital recordkeeping that accelerate method transfer between sites and support harmonized documentation suitable for regulatory inspection.

Third, prioritize solutions that demonstrate matrix compatibility across blood, tissue, and environmental samples so that a single platform can address multiple use cases, reducing complexity and total implementation burden. Fourth, strengthen partnerships between quality, regulatory, and laboratory functions to ensure that inactivation protocols are selected and validated with both scientific rigor and operational practicality in mind. This cross-functional alignment helps avoid rework and supports quicker adoption.

Fifth, consider service-based models or vendor partnerships that include method development and ongoing verification services to lower internal burden and to accelerate access to validated workflows. Finally, build internal capability for continuous process improvement so that incremental gains in throughput, reagent usage, and documentation quality compound over time and offset procurement pressures. By combining supply chain resilience, validation excellence, and customer-centric service models, leaders can sustain uninterrupted testing and production while maintaining regulatory compliance and cost discipline.

Comprehensive mixed-methods research design combining stakeholder interviews, technical literature synthesis, and scenario analysis to validate operational insights and procurement impacts

This research adopts a mixed-methods approach combining primary stakeholder interviews, expert consultations, and secondary technical literature appraisal to construct a comprehensive view of the viral inactivation testing landscape. Primary inputs included structured discussions with laboratory directors, quality assurance leads, procurement specialists, and technical operations managers across clinical, research, and manufacturing settings. These conversations focused on operational constraints, technology performance in real-world matrices, and validation requirements.

Secondary analysis drew on peer-reviewed publications, regulatory guidance documents, and manufacturer technical dossiers to cross-validate performance claims, method compatibilities, and documented validation endpoints. Where applicable, white papers and technical application notes were synthesized to clarify instrument operating ranges, consumable lifecycles, and compatibility with diagnostic assays and production workflows. Triangulation across data streams ensured that conclusions reflect both empirical evidence and observed practitioner behavior.

The methodology also incorporated scenario analysis to assess supply chain and tariff impacts, using representative case studies to illustrate procurement responses and resilience strategies. Throughout, emphasis was placed on transparency in data provenance and on clearly documenting methodological assumptions so that readers can interpret findings within their own operational and regulatory contexts.

Synthesis of strategic imperatives emphasizing validation, interoperability, and supplier resilience as the determinants of sustained operational performance in viral inactivation testing

In conclusion, viral inactivation testing has moved to the center of operational decision-making for clinical laboratories, research institutions, and manufacturers. Technological options have diversified to meet specific matrix and throughput needs, while regulatory and procurement pressures have elevated the importance of robust validation, digital recordkeeping, and supplier resilience. Organizations that proactively align technology selection with application requirements and that invest in cross-functional validation capacity will be better positioned to sustain operations and reduce risk in an environment of shifting trade policies and rising quality expectations.

Looking forward, leaders should expect continued emphasis on interoperability, demonstrable validation data, and flexible service models that reduce internal burden. By focusing on modular approaches that can be adapted across settings and by strengthening supplier and operational resilience, stakeholders can ensure continuity of testing and production while preserving scientific integrity and regulatory compliance. The strategic choices made today about platform selection, supplier relationships, and validation approaches will determine the agility and reliability of viral inactivation capabilities for years to come.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Medical Device Viral Inactivation Testing Market, by Technology

• 8.1. Chemical
• 8.2. Filtration
• 8.3. Heat
• 8.4. Uv C Irradiation

9. Medical Device Viral Inactivation Testing Market, by Testing Type

• 9.1. Qualitative
• 9.2. Quantitative

10. Medical Device Viral Inactivation Testing Market, by Setting

• 10.1. Lab Based
• 10.2. Point Of Care

11. Medical Device Viral Inactivation Testing Market, by Sample Type

• 11.1. Blood Samples
• 11.2. Environmental Samples
• 11.3. Tissue Samples

12. Medical Device Viral Inactivation Testing Market, by Application

• 12.1. Diagnostic Testing
  • 12.1.1. Hospital Laboratories
  • 12.1.2. Point Of Care Testing
• 12.2. Research Applications
• 12.3. Sterilization Services
• 12.4. Vaccine Production
  • 12.4.1. Inactivated Vaccines
  • 12.4.2. Live Attenuated Vaccines
  • 12.4.3. Recombinant Vaccines

13. Medical Device Viral Inactivation Testing Market, by End User

• 13.1. Diagnostic Centers
• 13.2. Hospitals And Clinics
• 13.3. Pharmaceutical Companies
• 13.4. Research Laboratories

14. Medical Device Viral Inactivation Testing Market, by Region

• 14.1. Americas
  • 14.1.1. North America
  • 14.1.2. Latin America
• 14.2. Europe, Middle East & Africa
  • 14.2.1. Europe
  • 14.2.2. Middle East
  • 14.2.3. Africa
• 14.3. Asia-Pacific

15. Medical Device Viral Inactivation Testing Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Medical Device Viral Inactivation Testing Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. United States Medical Device Viral Inactivation Testing Market

18. China Medical Device Viral Inactivation Testing Market

19. Competitive Landscape

• 19.1. Market Concentration Analysis, 2025
  • 19.1.1. Concentration Ratio (CR)
  • 19.1.2. Herfindahl Hirschman Index (HHI)
• 19.2. Recent Developments & Impact Analysis, 2025
• 19.3. Product Portfolio Analysis, 2025
• 19.4. Benchmarking Analysis, 2025
• 19.5. Bertin Technologies
• 19.6. BioMrieux
• 19.7. Charles River Laboratories
• 19.8. Ecovadis
• 19.9. Lonza
• 19.10. MedDevice
• 19.11. Merck KGaA
• 19.12. Pall Corporation
• 19.13. SGS
• 19.14. Sterigenics
• 19.15. The Biovac Initiative
• 19.16. Thermo Fisher Scientific
• 19.17. ViroStat
• 19.18. WuXi AppTec

LIST OF FIGURES

• FIGURE 1. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SHARE, BY KEY PLAYER, 2025
• FIGURE 3. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET, FPNV POSITIONING MATRIX, 2025
• FIGURE 4. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 5. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TESTING TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 7. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 9. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 11. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 13. UNITED STATES MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 14. CHINA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

• TABLE 1. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 2. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 3. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY CHEMICAL, BY REGION, 2018-2032 (USD MILLION)
• TABLE 4. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY CHEMICAL, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 5. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY CHEMICAL, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 6. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY FILTRATION, BY REGION, 2018-2032 (USD MILLION)
• TABLE 7. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY FILTRATION, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 8. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY FILTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 9. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY HEAT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 10. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY HEAT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 11. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY HEAT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 12. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY UV C IRRADIATION, BY REGION, 2018-2032 (USD MILLION)
• TABLE 13. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY UV C IRRADIATION, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 14. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY UV C IRRADIATION, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 15. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
• TABLE 16. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY QUALITATIVE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 17. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY QUALITATIVE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 18. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY QUALITATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 19. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY QUANTITATIVE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 20. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY QUANTITATIVE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 21. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY QUANTITATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 22. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
• TABLE 23. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY LAB BASED, BY REGION, 2018-2032 (USD MILLION)
• TABLE 24. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY LAB BASED, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 25. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY LAB BASED, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 26. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 27. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY POINT OF CARE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 28. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 29. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 30. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY BLOOD SAMPLES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 31. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY BLOOD SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 32. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY BLOOD SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 33. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY ENVIRONMENTAL SAMPLES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 34. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY ENVIRONMENTAL SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 35. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY ENVIRONMENTAL SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 36. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TISSUE SAMPLES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 37. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TISSUE SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 38. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TISSUE SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 39. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 40. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, BY REGION, 2018-2032 (USD MILLION)
• TABLE 41. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 42. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 43. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2032 (USD MILLION)
• TABLE 44. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 45. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 46. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 47. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY POINT OF CARE TESTING, BY REGION, 2018-2032 (USD MILLION)
• TABLE 48. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY POINT OF CARE TESTING, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 49. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY POINT OF CARE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 50. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY RESEARCH APPLICATIONS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 51. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY RESEARCH APPLICATIONS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 52. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY RESEARCH APPLICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 53. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY STERILIZATION SERVICES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 54. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY STERILIZATION SERVICES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 55. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY STERILIZATION SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 56. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY VACCINE PRODUCTION, BY REGION, 2018-2032 (USD MILLION)
• TABLE 57. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY VACCINE PRODUCTION, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 58. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY VACCINE PRODUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 59. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY VACCINE PRODUCTION, 2018-2032 (USD MILLION)
• TABLE 60. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 61. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY INACTIVATED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 62. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY INACTIVATED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 63. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 64. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 65. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 66. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY RECOMBINANT VACCINES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 67. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY RECOMBINANT VACCINES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 68. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY RECOMBINANT VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 69. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 70. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 71. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 72. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 73. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 74. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 75. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 76. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 77. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 78. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 79. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 80. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 81. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 82. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 83. AMERICAS MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 84. AMERICAS MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 85. AMERICAS MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
• TABLE 86. AMERICAS MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
• TABLE 87. AMERICAS MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 88. AMERICAS MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 89. AMERICAS MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2032 (USD MILLION)
• TABLE 90. AMERICAS MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY VACCINE PRODUCTION, 2018-2032 (USD MILLION)
• TABLE 91. AMERICAS MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 92. NORTH AMERICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 93. NORTH AMERICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 94. NORTH AMERICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
• TABLE 95. NORTH AMERICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
• TABLE 96. NORTH AMERICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 97. NORTH AMERICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 98. NORTH AMERICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2032 (USD MILLION)
• TABLE 99. NORTH AMERICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY VACCINE PRODUCTION, 2018-2032 (USD MILLION)
• TABLE 100. NORTH AMERICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 101. LATIN AMERICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 102. LATIN AMERICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 103. LATIN AMERICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
• TABLE 104. LATIN AMERICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
• TABLE 105. LATIN AMERICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 106. LATIN AMERICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 107. LATIN AMERICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2032 (USD MILLION)
• TABLE 108. LATIN AMERICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY VACCINE PRODUCTION, 2018-2032 (USD MILLION)
• TABLE 109. LATIN AMERICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 110. EUROPE, MIDDLE EAST & AFRICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 111. EUROPE, MIDDLE EAST & AFRICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 112. EUROPE, MIDDLE EAST & AFRICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
• TABLE 113. EUROPE, MIDDLE EAST & AFRICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
• TABLE 114. EUROPE, MIDDLE EAST & AFRICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 115. EUROPE, MIDDLE EAST & AFRICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 116. EUROPE, MIDDLE EAST & AFRICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2032 (USD MILLION)
• TABLE 117. EUROPE, MIDDLE EAST & AFRICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY VACCINE PRODUCTION, 2018-2032 (USD MILLION)
• TABLE 118. EUROPE, MIDDLE EAST & AFRICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 119. EUROPE MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 120. EUROPE MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 121. EUROPE MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
• TABLE 122. EUROPE MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
• TABLE 123. EUROPE MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 124. EUROPE MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 125. EUROPE MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2032 (USD MILLION)
• TABLE 126. EUROPE MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY VACCINE PRODUCTION, 2018-2032 (USD MILLION)
• TABLE 127. EUROPE MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 128. MIDDLE EAST MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 129. MIDDLE EAST MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 130. MIDDLE EAST MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
• TABLE 131. MIDDLE EAST MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
• TABLE 132. MIDDLE EAST MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 133. MIDDLE EAST MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 134. MIDDLE EAST MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2032 (USD MILLION)
• TABLE 135. MIDDLE EAST MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY VACCINE PRODUCTION, 2018-2032 (USD MILLION)
• TABLE 136. MIDDLE EAST MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 137. AFRICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 138. AFRICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 139. AFRICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
• TABLE 140. AFRICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
• TABLE 141. AFRICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 142. AFRICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 143. AFRICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2032 (USD MILLION)
• TABLE 144. AFRICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY VACCINE PRODUCTION, 2018-2032 (USD MILLION)
• TABLE 145. AFRICA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 146. ASIA-PACIFIC MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 147. ASIA-PACIFIC MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 148. ASIA-PACIFIC MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
• TABLE 149. ASIA-PACIFIC MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
• TABLE 150. ASIA-PACIFIC MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 151. ASIA-PACIFIC MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 152. ASIA-PACIFIC MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2032 (USD MILLION)
• TABLE 153. ASIA-PACIFIC MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY VACCINE PRODUCTION, 2018-2032 (USD MILLION)
• TABLE 154. ASIA-PACIFIC MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 155. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 156. ASEAN MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 157. ASEAN MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 158. ASEAN MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
• TABLE 159. ASEAN MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
• TABLE 160. ASEAN MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 161. ASEAN MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 162. ASEAN MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2032 (USD MILLION)
• TABLE 163. ASEAN MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY VACCINE PRODUCTION, 2018-2032 (USD MILLION)
• TABLE 164. ASEAN MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 165. GCC MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 166. GCC MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 167. GCC MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
• TABLE 168. GCC MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
• TABLE 169. GCC MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 170. GCC MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 171. GCC MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2032 (USD MILLION)
• TABLE 172. GCC MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY VACCINE PRODUCTION, 2018-2032 (USD MILLION)
• TABLE 173. GCC MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 174. EUROPEAN UNION MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 175. EUROPEAN UNION MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 176. EUROPEAN UNION MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
• TABLE 177. EUROPEAN UNION MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
• TABLE 178. EUROPEAN UNION MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 179. EUROPEAN UNION MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 180. EUROPEAN UNION MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2032 (USD MILLION)
• TABLE 181. EUROPEAN UNION MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY VACCINE PRODUCTION, 2018-2032 (USD MILLION)
• TABLE 182. EUROPEAN UNION MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 183. BRICS MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 184. BRICS MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 185. BRICS MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
• TABLE 186. BRICS MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
• TABLE 187. BRICS MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 188. BRICS MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 189. BRICS MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2032 (USD MILLION)
• TABLE 190. BRICS MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY VACCINE PRODUCTION, 2018-2032 (USD MILLION)
• TABLE 191. BRICS MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 192. G7 MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 193. G7 MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 194. G7 MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
• TABLE 195. G7 MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
• TABLE 196. G7 MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 197. G7 MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 198. G7 MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2032 (USD MILLION)
• TABLE 199. G7 MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY VACCINE PRODUCTION, 2018-2032 (USD MILLION)
• TABLE 200. G7 MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 201. NATO MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 202. NATO MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 203. NATO MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
• TABLE 204. NATO MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
• TABLE 205. NATO MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 206. NATO MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 207. NATO MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2032 (USD MILLION)
• TABLE 208. NATO MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY VACCINE PRODUCTION, 2018-2032 (USD MILLION)
• TABLE 209. NATO MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 210. GLOBAL MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 211. UNITED STATES MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 212. UNITED STATES MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 213. UNITED STATES MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
• TABLE 214. UNITED STATES MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
• TABLE 215. UNITED STATES MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 216. UNITED STATES MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 217. UNITED STATES MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2032 (USD MILLION)
• TABLE 218. UNITED STATES MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY VACCINE PRODUCTION, 2018-2032 (USD MILLION)
• TABLE 219. UNITED STATES MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 220. CHINA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 221. CHINA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 222. CHINA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
• TABLE 223. CHINA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SETTING, 2018-2032 (USD MILLION)
• TABLE 224. CHINA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 225. CHINA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 226. CHINA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2032 (USD MILLION)
• TABLE 227. CHINA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY VACCINE PRODUCTION, 2018-2032 (USD MILLION)
• TABLE 228. CHINA MEDICAL DEVICE VIRAL INACTIVATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)